PSMA617 TFA
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206934

CAS#: 1702967-37-0 (free base)

Description: PSMA-617 is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer,. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development.


Price and Availability

Size
Price

1mg
USD 190
10mg
USD 1250
Size
Price

2mg
USD 350
25mg
USD 2650
Size
Price

5mg
USD 750
50mg
USD 4450

PSMA-617 TFA salt, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 206934
Name: PSMA617 TFA
CAS#: 1702967-37-0 (free base)
Chemical Formula: C57H75F12N9O24
Exact Mass: 1041.5019
Molecular Weight: 1498.25
Elemental Analysis: C, 45.70; H, 5.05; F, 15.22; N, 8.41; O, 25.63


Related CAS #: 1702967-37-0 (free base)   CAS# unknown (TFA salt)    

Synonym: PSMA-617; PSMA617; PSMA 617; PSMA617 TFA; PSMA617 triflouroacetic acid salt

IUPAC/Chemical Name: (((S)-1-carboxy-5-((S)-3-(naphthalen-2-yl)-2-((1r,4S)-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)-L-glutamic acid tetra(trifluoroacetic acid)

InChi Key: JBHPLHATEXGMQR-LFWIOBPJSA-N

InChi Code: InChI=1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32-,35-,37-,38-,39-/m0/s1

SMILES Code: O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CC(O)=O)NC[C@H]2CC[C@@H](CC2)C(N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC3=CC=C4C=CC=CC4=C3)=O


Technical Data

Appearance:
White to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in water and ethanol.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934990300


References

1: Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28. PubMed PMID: 29262549; PubMed Central PMCID: PMC5732715.

2: von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2017 Dec 16. doi: 10.1007/s00259-017-3895-x. [Epub ahead of print] Review. PubMed PMID: 29247284.

3: Rahbar K, Ahmadzadehfar H, Boegemann M. (177)Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? Eur J Nucl Med Mol Imaging. 2017 Nov 21. doi: 10.1007/s00259-017-3892-0. [Epub ahead of print] PubMed PMID: 29164300.

4: Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F. Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017. PubMed PMID: 29158832; PubMed Central PMCID: PMC5695136.

5: Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Nov 13. doi: 10.1007/s00259-017-3877-z. [Epub ahead of print] PubMed PMID: 29134280.

6: Iori M, Capponi PC, Rubagotti S, Esposizione LR, Seemann J, Pitzschler R, Dreger T, Formisano D, Grassi E, Fioroni F, Versari A, Asti M. Labelling of (90)Y- and (177)Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis. Contrast Media Mol Imaging. 2017 May 25;2017:8160134. doi: 10.1155/2017/8160134. eCollection 2017. PubMed PMID: 29097938; PubMed Central PMCID: PMC5612754.

7: Han XD, Liu C, Liu F, Xie QH, Liu TL, Guo XY, Xu XX, Yang X, Zhu H, Yang Z. (64)Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget. 2017 May 26;8(43):74159-74169. doi: 10.18632/oncotarget.18276. eCollection 2017 Sep 26. PubMed PMID: 29088775; PubMed Central PMCID: PMC5650330.

8: Kelly JM, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Vallabhajosula S, Babich JW. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of (68)Ga(3+), (111)In(3+), (177)Lu(3+) and (225)Ac(3). Nucl Med Biol. 2017 Dec;55:38-46. doi: 10.1016/j.nucmedbio.2017.10.001. Epub 2017 Oct 3. PubMed PMID: 29055836.

9: von Eyben FE, Kiljunen T, Joensuu T, Kairemo K, Uprimny C, Virgolini I. (177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer. Oncotarget. 2017 Aug 2;8(39):66112-66116. doi: 10.18632/oncotarget.19805. eCollection 2017 Sep 12. PubMed PMID: 29029496; PubMed Central PMCID: PMC5630396.

10: Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19. doi: 10.1007/s00259-017-3848-4. Epub 2017 Oct 12. PubMed PMID: 29026946.

11: Du Y, Dizdarevic S. Molecular radiotheragnostics in prostate cancer. Clin Med (Lond). 2017 Oct;17(5):458-461. doi: 10.7861/clinmedicine.17-5-458. PubMed PMID: 28974599.

12: Dam JH, Olsen BB, Baun C, Høilund-Carlsen PF, Thisgaard H. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Mol Imaging Biol. 2017 Dec;19(6):915-922. doi: 10.1007/s11307-017-1121-7. PubMed PMID: 28924629.

13: Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M. Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride. Oncotarget. 2017 Feb 25;8(33):55567-55574. doi: 10.18632/oncotarget.15698. eCollection 2017 Aug 15. PubMed PMID: 28903443; PubMed Central PMCID: PMC5589682.

14: Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, Haberkorn U, Giesel FL. Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37. doi: 10.1007/s00259-017-3817-y. Epub 2017 Sep 11. PubMed PMID: 28891033; PubMed Central PMCID: PMC5700223.

15: Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S. doi: 10.2967/jnumed.116.186775. Review. PubMed PMID: 28864607.

16: Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, Haberkorn U, Kratochwil C. Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq. J Nucl Med. 2017 Aug 10. pii: jnumed.117.194209. doi: 10.2967/jnumed.117.194209. [Epub ahead of print] PubMed PMID: 28798031.

17: Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer. Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763. PubMed PMID: 28719450.

18: Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, Rahbar K. (177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670. doi: 10.1007/s00259-017-3751-z. Epub 2017 Jun 17. PubMed PMID: 28624848.

19: Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivanoğlu H, Alan Selçuk N. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68. doi: 10.4274/mirt.08760. PubMed PMID: 28613198; PubMed Central PMCID: PMC5472088.

20: Schlenkhoff CD, Essler M, Ahmadzadehfar H. Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617. Clin Nucl Med. 2017 Aug;42(8):639-640. doi: 10.1097/RLU.0000000000001715. PubMed PMID: 28574879.